STOCKHOLM, SWEDEN / ACCESSWIRE / April 9, 2024 / In a significant leap for financial technology, GENERALIFX, a rapidly expanding name in AI-powered automated trading software and investment management consultancy, announces the launch of its latest innovation. This cutting-edge AI trading tool, designed to transform global financial market forecasts, is redefining investment strategies with its comprehensive, data-driven approach.
Harnessing an innovative amalgamation of technical and fundamental analysis, GENERALIFX has developed its software to simplify the intricate task of data analysis, thus equipping investors with instantaneous insights into market trends and predictive analytics for superior decision-making. This sophisticated technology scrutinizes data from economic and earnings calendars and integrates direct feeds from the premier terminals for financial news and market data, which are crucial for finance professionals, delivering real-time access to exhaustive market data, news, and analytical tools. Such comprehensive integration ensures the provision of precise forecasts across a multitude of trading platforms. With the deployment of this technology, GENERALIFX democratizes success in trading, making it accessible not only to seasoned professionals but also to novices, thereby bridging the gap between experience levels and empowering every investor to achieve success in the financial markets.
"By harnessing the power of our unique AI model, we’re not just predicting market movements; we’re offering a suite of tools designed for modern investors. From identifying undervalued stocks using sophisticated algorithms to providing advanced risk assessment tools, our software is a game-changer," says Henrik Stenbergsson, CTO at GENERALIFX.
Empowering Investors with Cutting-Edge Features:
Automated Data Analysis: Saves time by automating the analysis of vast amounts of market data.
Real-Time Insights and Trends: Delivers up-to-the-minute market insights and trends.
Predictive Analytics: Enhances decision-making with predictive analytics based on historical and current market data.
Undervalued Stock Identification: Uses algorithms to spot potentially undervalued stocks.
Instant Global Event Monitoring: Keeps tabs on global events for their immediate impact on markets.
Personalized Risk Management: Tailors strategies to individual risk tolerances, optimizing for both safety and performance.
Strategy Testing via Simulations: Allows investors to test strategies through simulations before actual implementation.
AI-Driven Portfolio Diversification: Recommends portfolio diversification strategies based on AI analysis.
Pattern Detection: Detects subtle patterns in stock performance for early investment opportunities.
Emotional Bias Minimization: Helps minimize the emotional biases commonly associated with investing.
Financial News and Social Media Analysis: Tracks financial news and analyzes social media for sentiment trends impacting markets.
Advanced Risk Assessment Tools: Provides tools for a more nuanced understanding of potential risks.
Big Data Insights: Facilitates access to and interpretation of big data insights.
Dynamic Asset Allocation: Optimizes asset allocation dynamically to respond to market changes.
Trade Entry and Exit Advisories: Advises on the best times to enter or exit trades.
Securities Screening: Screens securities for a range of fundamental and technical indicators.
Market Cycle Understanding: Improves investors’ understanding of market cycles for better timing decisions.
Portfolio Rebalancing Efficiency: Enhances the efficiency and timing of portfolio rebalancing.
By integrating these features, GENERALIFX not only simplifies the investment process but also empowers investors to make informed, data-backed decisions. This innovation is set to solidify GENERALIFX’s position as a leader in the fintech space, offering both novice and experienced investors alike the tools to navigate the complexities of the global markets with confidence and precision.
For more information about GENERALIFX and to discover the future of automated trading and investment management, visit www.GENERALIFX.com.
About GENERALIFX
GENERALIFX is a pioneering provider of AI-powered automated trading software and global investment management consultancy services. With a commitment to innovation, reliability, and excellence, GENERALIFX delivers unparalleled trading tools and strategic investment solutions, meeting the evolving needs of the global financial markets since 2017.
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / April 9, 2024 / USPA Global has announced that U.S. Polo Assn., the official brand of the United States Polo Association (USPA), has delivered a record $2.4 billion in global retail sales in 2023.
The global sports brand’s record growth is the result of expanding its existing sizeable footprint across all regions around the world. U.S. Polo Assn. has seen a balanced growth strategy with significantly increased market share in more mature markets, such as North America and Western Europe, while delivering exponential growth in emerging markets such as Asia, Latin America, the Middle East, and India. In fact, the brand is targeting to become a billion-dollar business in India alone, as U.S. Polo Assn. is an international power brand and the top-selling casual menswear brand in the country.
The brand’s footprint is a fast-growing presence across 190 countries, with over 1,100 U.S. Polo Assn. retail stores and thousands of wholesale locations spanning department stores, sporting goods channels, and independent retailers, as well as e-commerce. U.S. Polo Assn. continues to climb the retail ranks as one of the largest global licensed sports brands in the world, ranking in the top five alongside the NFL, MLB, and NBA, according to License Global.
U.S. Polo Assn.’s strong execution has relied on a global focus regarding the brand’s worldwide store expansion. The brand has grown its global fleet to more than 1,100 U.S. Polo Assn. stores, targeting over 1,500 in the next several years. For 2023, new stores and existing strategic stores around the world have been enhanced with a more elevated brand and sports concept, providing consumers with an authentic experience when engaging with the brand.
U.S. Polo Assn. also built on its successful digital strategies to generate record growth in e-commerce with some 50 brand sites in 20 languages in 2023. U.S. Polo Assn. continues to grow its digital presence and global momentum on social media, with some 8 million followers worldwide.
"Our global team and strategic partners around the world delivered another record financial performance in 2023 while also achieving many major milestones across our product lines and global expansion efforts," noted J. Michael Prince, President & CEO of USPA Global. "We continue to execute our aggressive product, store, digital, and international growth strategies to further expand our global footprint in key cities and markets worldwide, while also increasing the overall interest in the sport of polo."
Prince added, "Despite the many challenges over the past several years facing global retail, U.S. Polo Assn. was able to exceed our goal of $2 billion three years early and has set a target to hit $3 billion and 1,500 U.S. Polo Assn. stores in the near future."
True to the heritage of the brand, U.S. Polo Assn. maintains a strong connection to the sport of polo. By signing a recent landmark multi-year global deal with ESPN, the thrilling sport now has exposure to a massive global audience, extending to many parts of the world with reach to millions of households and multiple digital channels. The sport’s iconic U.S. Open Polo Championship®, which is broadcast by ESPN, now sits alongside the elite company of The Masters and Kentucky Derby as one of the country’s most prestigious spring sporting events.
In addition, the USPA now owns the USPA National Polo Center (NPC), the sport’s premier destination in North America. The 2024 American High-Goal Polo Season has brought record crowds and sellout Sundays, with the best polo in the world from January-April. Nestled in beautiful Palm Beach County, Florida, this outstanding venue spans 160 acres, encompassing multiple grass polo fields, fine dining, tennis courts, stadium seating, a swimming pool, and the NPC Retail Shop. Exciting updates to the world-class facility are slated for 2025.
"We continue to seek avenues and partnerships to expand into new global markets, as well as new and innovative areas of business. The combination of these factors, alongside our authentic connection to the sport of polo and outstanding global brand marketing, is the key to our global success," Prince adds. "I am optimistic about the U.S. Polo Assn. global business maintaining its leadership position among its industry peers while gaining market share and our ability to reach over $3 billion in worldwide sales and 1,500 U.S. Polo Assn. retail stores in the coming years."
"Today, I am proud to say that our U.S. Polo Assn. global ecosystem is comprehensive of both the brand and the sport, with our $2.4 billion global sport-inspired brand, a global sports content platform with ESPN, and ownership of NPC, one of the sport’s most beautiful and prestigious venues," concludes Prince.
About U.S. Polo Assn. and USPA Global
U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the governing body for the sport of polo in the United States and one of the country’s oldest sports governing bodies, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. A recent, multi-year deal with ESPN to broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., has made the thrilling sport accessible to millions of sports fans globally for the very first time.
U.S. Polo Assn. has consistently been named one of the top global sports licensors alongside the NFL, NBA, and MLB, according to License Global. In addition, the sport-inspired brand is being recognized around the world with awards for global growth, expansion, licensing, and digital growth. Due to its tremendous success as a global brand, particularly in the last five years, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world.
USPA Global is a subsidiary of the USPA and manages the global, multi-billion-dollar U.S. Polo Assn. brand, providing the sport with a long-term source of revenue. Through its subsidiary, Global Polo Entertainment (GPE), USPA Global also manages Global Polo TV, which provides sport and lifestyle content. For more sports content, visit globalpolo.com.
Contact Information
Stacey Kovalsky VP Global PR and Communications skovalsky@uspagl.com +001.561.790.8036
The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI’s single dose Lassa fever vaccine candidate
Key takeaways:
Participants in Nigeria have been vaccinated with a Lassa fever vaccine candidate in the first Phase 2 clinical trial of any Lassa vaccine.
Lassa fever is a deadly hemorrhagic fever common to West Africa. No approved vaccine currently exists.
More than 600 participants in Ghana, Liberia, and Nigeria are expected to enroll in the IAVI-sponsored trial, funded by CEPI.
NEW YORK, NY / ACCESSWIRE / April 4, 2024 / Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor. The study (IAVI C105/PREVAIL15) is funded by CEPI, an innovative global partnership working to accelerate the development of vaccines against epidemic and pandemic threats.
Dr. Bolaji (left) is the Nigeria-based HJFMRI principal investigator for the IAVI C105 Lassa fever vaccine clinical trial at HJFMRI in Abuja, Nigeria
The trial in Nigeria has been designed in consultation with in-country partners, including the Nigeria Centre for Disease Control and Prevention and the Nigeria Lassa Vaccine Taskforce. HJF Medical Research International, Ltd/Gte (HJFMRI) has been conducting infectious diseases research in collaboration with HJF and the Walter Reed Army Institute of Research in Nigeria since 2014. In addition to Nigeria, and pending regulatory approval, IAVI expects to enroll additional participants at the Noguchi Memorial Institute for Medical Research (NMIMR), College of Health Sciences, University of Ghana, and the Partnership for Research on Vaccines and Infectious Diseases in Liberia (PREVAIL)1.
"Nigerian clinicians, scientists and community members are key leaders in this international collaboration, which will ensure that vaccine development incorporates local context, experience and perspectives while fostering sustainable in-country research capacity and partnerships," said Dr. Abdulwasiu Bolaji Tiamiyu, clinical research center director, HJFMRI, and principal investigator of IAVI C105 in Nigeria.
No approved vaccine currently exists for LASV, which causes an acute viral hemorrhagic illness called Lassa fever. Given its potential to cause a public health emergency of international concern, LASV is included in the World Health Organization R&D Blueprint of priority pathogens for which there is an urgent need for accelerated research and development (R&D) and countermeasures2. IAVI and members of the global Viral Hemorrhagic Fever Consortium have been collaborating since 2018 to accelerate clinical development of IAVI’s single-dose LASV vaccine candidate in studies supported and funded by CEPI and the European & Developing Countries Clinical Trials Partnership (EDCTP). Read more.
An estimated 5,000 people die each year from LASV, and about 300,000 people fall ill across West Africa annually – though the true disease burden is thought to be much higher. Nigeria, Liberia, Sierra Leone, and Guinea are most affected, but increasingly, neighboring countries are experiencing their own emerging outbreaks, with travelers occasionally carrying infections to other regions. Although most people who develop LASV have mild or no symptoms, approximately 20% will develop more serious symptoms including widespread bleeding and major organ failure. Approximately a third of those infected with LASV experience associated deafness, sometimes resulting in lifelong disability. Children under 10 years old, pregnant people, and health care workers are especially vulnerable to LASV infection.
"Continued outbreaks of Lassa fever and the emergence of Ebola Sudan in Uganda both underscore the need to have vaccines for known disease threats available for evaluation and use during outbreak situations – the overarching goal of IAVI’s emerging infectious disease program." said Swati Gupta, DrPH, MPH, vice president and head of emerging infectious diseases and epidemiology, IAVI. "IAVI C105 is an important step toward attaining eventual licensure of a Lassa fever vaccine, should IAVI’s vaccine candidate prove to have an acceptable safety profile and be efficacious. We are grateful to our funders, our clinical partners, and our consortium collaborators for their continued support of IAVI and commitment to a more secure world."
"Lassa fever has long been a threat to much of West Africa, and factors like climate change and population growth could exacerbate its transmission in coming decades," explains Dr. Richard Hatchett, CEO of CEPI. "The world urgently needs a Lassa vaccine for routine immunisation. The initiation of IAVI’s new Phase 2 trial – the most advanced Lassa vaccine trial to date – is an important milestone in public health and signals that better tools to manage and prevent outbreaks are coming. We look forward to continuing to collaborate with IAVI and regional partners to advance this promising vaccine as quickly as possible."
IAVI’s LASV vaccine candidate was well-tolerated and immunogenic among participants in both the U.S. and Liberian cohorts of IAVI’s Phase I LASV vaccine trial (IAVI C102). Robust immune responses appear to be sustained for up to one year after vaccination3. In the Phase 2 study, researchers will evaluate the vaccine candidate’s safety, tolerability, and immunogenicity at two different dosage levels in adults, including people living with HIV, as well as in adolescents and in children two years of age and older. Approximately 612 participants will be enrolled and followed for six months after vaccination to monitor their safety and immune responses. A subset of participants will be followed for an additional two years for extended safety and immunogenicity.
CEPI and IAVI are united in their commitment to global equitable access. Should the candidate be found to be safe and efficacious in clinical testing, IAVI is committed to making its Lassa vaccine affordable and accessible to all populations in need.
Harnessing a proven platform technology for global preparedness
IAVI’s LASV vaccine candidate uses the same recombinant vesicular stomatitis virus (rVSV) vector platform as ERVEBO®, Merck’s single-dose Zaire ebolavirus (ZEBOV) vaccine, which is licensed in North America, Europe, and 10 African countries. The rVSV platform has been used extensively in adults and children4.
IAVI’s goal is to develop and test rVSV-based vaccines against emerging infectious disease pathogens that pose epidemic threats as part of an overall preventive strategy which includes routine immunization as appropriate as well as stockpiles which can be rapidly deployed for larger outbreaks as needed. IAVI’s EID portfolio includes a Sudan ebolavirus vaccine candidate supported by BARDA; a Lassa fever vaccine candidate supported by CEPI and EDCTP; a Marburg virus vaccine candidate supported by BARDA and the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD); and an intranasal SARS-CoV-2 vaccine candidate supported by DOD DTRA and the Japan Ministry of Finance.
Much of the R&D on IAVI’s rVSV platform is performed at the IAVI Vaccine Design and Development Lab (DDL) in Brooklyn, New York. The DDL is one of the world’s leading viral vector vaccine R&D labs, known for innovation and generation of novel vaccine design concepts. Scientists with IAVI’s Human Immunology Laboratory (HIL) in London, U.K., are involved in processing participant samples and developing the analytical assays needed to evaluate IAVI C105 participants’ immune responses. They are also facilitating technology transfer of the assays to West African partner institutions.
IAVI’s LASV vaccine candidate was manufactured by Batavia Biosciences in Leiden, The Netherlands, a contract-development and manufacturing organization focused on delivering sustainable, low-cost manufacturing solutions in the field of infectious disease and cancer. Through its partnership with Batavia, IAVI intends to develop an end-to-end platform for flexible, low-cost production of epidemic preparedness vaccines.
Results from IAVI C105 are expected in 2025 and will be made available through open-access publications and via scientific meetings to ensure all can benefit from the research.
IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV, tuberculosis, and emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health solutions. Read more at iavi.org.
CEPI was launched in 2017 as an innovative partnership between public, private, philanthropic and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.
About IAVI’s rVSV vaccine candidates
IAVI holds a nonexclusive license to the rVSV vaccine candidates from the Public Health Agency of Canada (PHAC). The vector was developed by scientists at PHAC’s National Microbiology Laboratory.
IAVI initially developed its rVSV vector for HIV vaccine candidates and has since expanded its use to the development of vaccines addressing emerging infectious diseases (Lassa Fever, Marburg, Sudan ebolavirus, and COVID-19).
Funders who have made the development of IAVI’s rVSV-vectored vaccine candidates possible include the Bill & Melinda Gates Foundation; the Government of Canada; the Danish Ministry of Foreign Affairs; the Government of Japan; the Irish Department of Foreign Affairs and Trade; the Netherlands Ministry of Foreign Affairs; the Norwegian Agency for Development Cooperation; the U.K. Foreign, Commonwealth & Development Office; the U.S. National Institutes of Health; and through the generous support of the American people from the United States Agency for International Development.
This project is funded in whole or in part with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority under contract number 75A50121C00077.
1 PREVAIL is a Liberia-U.S. clinical research collaboration established in 2014 by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Ministry of Health in Liberia. In 2015, PREVAIL participated in a clinical trial (PREVAIL 1) of Merck’s now-licensed Ebola Zaire vaccine ERVEBO®, which uses the same recombinant vesicular stomatitis virus (rVSV) vector backbone as the candidates in IAVI’s emerging infectious diseases (EIDs) vaccine development portfolio, including the IAVI LASV vaccine candidate being evaluated in a Phase I clinical trial.
KONONGO, GHANA / ACCESSWIRE / February 29, 2024 / Konongo St. Gabriel’s Co-Operate Credit Union takes a bold step forward in safeguarding its digital infrastructure by partnering with OMNICOMMANDER® to bring industry-specific cybersecurity education to the entire staff and board of directors at the credit union.
"We are thrilled to announce this transformative partnership with OMNICOMMANDER," stated Angela Arko Nyaneba, CEO of Konongo St. Gabriel’s Co-Operate Credit Union. "Cybersecurity is not just a technical challenge; it’s a strategic imperative for our credit union. By deploying OMNICOMMANDDER’s expertise and resources, we aim to raise the bar for cybersecurity standards at our credit union and to empower the entire organization to navigate the evolving threat landscape with confidence and resilience."
The Bank of Ghana, the Central Bank in Ghana, initiated a Financial Industry Command Security Operations Center in 2019 to help prevent and respond to cyber threats aimed at the financial services sector. These initiatives are helping to bring additional resources and awareness to the evolving threats facing financial institutions throughout Ghana. OMNICOMMANDER’s cybersecurity division, CYBERCOMMANDER, has also taken notice of the emerging needs in the region and sought a partnership with Konongo St. Gabriel’s as their commitment to the credit union movement aligned well with OMNICOMMANDER’s global mission.
"The initial collaboration will provide access to OMNICOMMNADER’s cybersecurity awareness training through its CYBERCOMMANDER division and will make available a wide range of services," said Eric Isham, Founder and CEO of OMNICOMMANDER. "Our cybersecurity suite, including Risk Assessment, IT Security Audit, Vulnerability Assessment, External Penetration Test, Security Awareness Training, and specialized Remote Social Engineering Tests, alongside Tabletop Testing for Disaster Recovery and Business Continuity Plans, offers credit unions a comprehensive strategy to fortify their defenses against cyber threats. Through these targeted services, we empower credit unions not only to identify and mitigate vulnerabilities before they can be exploited but also to ensure their teams are prepared against the evolving landscape of cyber threats. I am thrilled to partner with our first credit union in Ghana."
"Our partnership with OMNICOMMANDER represents a significant milestone in our mission to enhance cybersecurity resilience within the credit union and hopefully across Ghana. When I met Eric in Vancouver last summer, I knew he was the right partner to bring these services to Africa," said Peter Sula Esq, Board Chairman for Konongo St. Gabriel’s Co-Operate Credit Union.
About OMNICOMMANDER
OMNICOMMANDER is a global leader in Digital Technology, Marketing, and Cybersecurity services for small to medium-sized financial institutions. In today’s digital landscape, financial institutions face challenges from online competition, engaging younger demographics, and evolving cyber threats. OMMNICOMMANDER’s comprehensive suite of solutions is purposely designed to address these challenges. It includes a feature-rich website solution called a BRANCHCOMMANDER, Integrated Marketing that drives demand, and Cybersecurity for maximizing FI regulatory compliance and institution-wide protection. To learn more about OMNICOMMANDER, please visit https://www.omnicommander.com/
About Konongo St. Gabriel’s Co-Operate Credit Union Ltd.
Konongo St. Gabriel’s Co-operative Credit Union is a financial co-operative society established in 1968. Initially established to serve only Catholic school teachers, it has expanded over the years to serve the community’s growing needs beyond the teaching profession. Its mission is to provide quality services that improve the living standards of all members through mobilization of funds, granting and recovering loans, and continuous community education and engagement. To learn more about St. Gariel’s Co-Operate Credit Union, please visit https://stgcculgh.com/. Media Contact
NEW YORK, NY / ACCESSWIRE / February 14, 2024 / The future of third-party diamond traceability and title of ownership from true origin is here. Authentia is proud to announce its official launch in South Africa following resounding success during its Beta testing phase. Since its introduction into the South African market, Authentia has secured agreements with 97 mines. Marking a monumental step forward in the realm of diamond and mineral authentication.
Authentia has spent the past year collaborating closely with small-scale and artisanal diamond mines to seamlessly integrate ownership titles of rough diamonds directly at the source. This groundbreaking approach ensures a transparent and accessible third-party verification process that follows each diamond throughout its entire lifecycle. Moreover, Authentia’ s adaptability ensures compatibility with a diverse array of technologies, promising a frictionless experience for all involved parties.
As a trailblazing oversight and traceability technology operating on public blockchains, Authentia sets the gold standard for tracking diamonds and gemstones from mine to market. By providing a comprehensive title of ownership, Authentia revolutionizes the industry by fostering transparency and trust among wholesalers, retailers, and end consumers alike.
CS Mines & CS Auctions is set to host for the first time a tender, featuring titled rough diamonds on. Bruno Scarselli, the visionary creator behind Authentia, expressed his excitement, stating, “This will change the diamond industry pipeline, streamlining all phases and creating a true footprint of ownership for the first time.”
Authentia stands as a testament to innovation and expertise, crafted by luminaries within the diamond, mineral and technology industry. Authentia emerges as a beacon of integrity within the gemstone and mineral market with an unwavering commitment to transparency, security, and trust.
NEW YORK, NY / ACCESSWIRE / February 14, 2024 / The future of third-party diamond traceability and title of ownership from true origin is here. Authentia is proud to announce its official launch in South Africa following resounding success during its Beta testing phase. Since its introduction into the South African market, Authentia has secured agreements with 97 mines. Marking a monumental step forward in the realm of diamond and mineral authentication.
Authentia has spent the past year collaborating closely with small-scale and artisanal diamond mines to seamlessly integrate ownership titles of rough diamonds directly at the source. This groundbreaking approach ensures a transparent and accessible third-party verification process that follows each diamond throughout its entire lifecycle. Moreover, Authentia’ s adaptability ensures compatibility with a diverse array of technologies, promising a frictionless experience for all involved parties.
As a trailblazing oversight and traceability technology operating on public blockchains, Authentia sets the gold standard for tracking diamonds and gemstones from mine to market. By providing a comprehensive title of ownership, Authentia revolutionizes the industry by fostering transparency and trust among wholesalers, retailers, and end consumers alike.
CS Mines & CS Auctions is set to host for the first time a tender, featuring titled rough diamonds on. Bruno Scarselli, the visionary creator behind Authentia, expressed his excitement, stating, "This will change the diamond industry pipeline, streamlining all phases and creating a true footprint of ownership for the first time."
Authentia stands as a testament to innovation and expertise, crafted by luminaries within the diamond, mineral and technology industry. Authentia emerges as a beacon of integrity within the gemstone and mineral market with an unwavering commitment to transparency, security, and trust.
, Integrated Marketing that drives demand, and Cybersecurity for maximizing FI regulatory compliance and institution-wide protection. To learn more about OMNICOMMANDER, please visit